Previous studies have therefore evaluated serum adiponectin in relation to cardiometabolic diseases and coronary heart disease, highlighting its potential as a biomarker for cardiac remodeling, arrhythmias, and other pathophysiological processes [7,10,11]. This evidence concerns the gene ADIPOQ and coronary artery disorder.